Android app Apple app link

Mural Oncology's Phase III ovarian cancer trial failure knocks stock by 57%

By Yahoo! Finance   |   1 week ago
Mural Oncology's Phase III ovarian cancer trial failure knocks stock by 57%

Mural Oncology halts nemvaleukin alfa development in ovarian cancer due to failed Phase III trial for platinum-resistant ovarian cancer. Stock value drops by 57%. CEO expresses disappointment but remains focused on other trials and data analysis for future decisions.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.